Across the past 12 months, open-market trades by Veraxa Biotech AG - Post de-SPAC insiders were all purchases, totaling $125,333 (95K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Oliver Rolf Baumann | Director | 0 | 5,773,618 | 5,773,618 | 99.1% | 31 Aug, 2026 |
| 2 | Christoph Samuel Ziegler | Director | 37,932 | 0 | 37,932 | 0.7% | 21 Oct, 2026 |
| 3 | Marc Gruninger | Director | 10,000 | 0 | 10,000 | 0.2% | 29 Oct, 2026 |
| 4 | Christoph Rudiger Antz | Chief Executive Officer | 5,000 | 0 | 5,000 | 0.1% | 31 Aug, 2026 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 27 Oct, 2026 | Marc Gruninger | Director | Acquired P | 867 | $0.98 | $850 | 867 | Direct |
| 28 Oct, 2026 | Marc Gruninger | Director | Acquired P | 9,133 | $1.00 | $9.13K | 10,000 | Direct |
| 20 Oct, 2026 | Christoph Samuel Ziegler | Director | Acquired P | 30,000 | $1.09 | $32.70K | 37,932 | Direct |
| 27 Aug, 2026 | Christoph Rudiger Antz | Chief Executive Officer | Acquired P | 5,000 | $1.53 | $7.65K | 5,000 | Direct |
| 27 Aug, 2026 | Oliver Rolf Baumann | Director | Acquired P | 50,000 | $1.50 | $75.00K | 5,773,618 | Indirect |